Mary Crowley Cancer Research Centers

What Mary Crowley Cancer Research Centers does

Mary Crowley Cancer Research Centers, founded in 1997 and headquartered in Dallas, Texas, is a private cancer research organization that operates a single-site clinical trial program for cancer patients in North Texas. Following its January 2025 integration with Sarah Cannon Research Institute (SCRI), the entity now operates under the unified brand "SCRI at Mary Crowley," offering access to an expanded clinical trial menu across a broad range of cancer types.

The organization's core service is the conduct of oncology clinical trials, delivered through physician referrals from the locally trusted Texas Oncology network and direct patient contact via phone and an online clinical trial finder. Its underlying technology stack is anchored by the Genospace personalized medicine platform, which transforms patient data into actionable treatment insights. Through the broader SCRI partner portfolio, the site also exposes patients and sponsors to additional offerings including Accelero™, oncology-focused CRO services, centralized SMO operations, and an Innovation, Science & Technology / Personalized Medicine service line.

Commercially, the organization functions as a professional services research site, generating revenue through clinical trial contracts and study sponsorships, with pricing not publicly disclosed and dependent on trial sponsorship, insurance coverage, and the mix of standard-of-care versus experimental treatment. The customer base is composed of individual cancer patients seeking access to cutting-edge therapies, with a patient acquisition motion driven by Texas Oncology physician referrals, social media presence, and the scri.com web channel. Management consists of a small clinical team of oncologists (Douglas Orr, MD; Reva Schneider, MD; Robert Mennel, MD; Nayyar Syed, MD) and advanced practice providers (Ntombizodwa Sayi; Keri Stenger).

Name

Mary Crowley Cancer Research Centers

Legal name

Mary Crowley Cancer Research Centers

Website

https://marycrowley.org

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

51–100 employees

Short description

Mary Crowley Cancer Research Centers, operating as SCRI at Mary Crowley since January 2025, is a Dallas-based cancer research site that runs oncology clinical trials for North Texas patients via Texas Oncology physician referrals, using the Genospace personalized medicine platform.

Ownership category

akta.pro rank

Product category

Cancer Clinical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Research & Trial Central Laboratories (HLAFAMAL)

Keywords

• Cancer clinical trials
• Oncology research services
• Personalized medicine platform
• Clinical research organization
• Site management organization

Headquarters

HQ city

Dallas

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Research Services: Mary Crowley Cancer Research operates as part of Sarah Cannon Research Institute (SCRI), providing clinical trial services for cancer patients. Revenue is generated through research contracts, study sponsorships, and healthcare services related to clinical trial conduct.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Mary Crowley Cancer Research Centers, operating as SCRI at Mary Crowley, conducts oncology clinical trials for cancer patients in North Texas, supported by Texas Oncology physicians. The center provides access to an expanded clinical trial menu, on-site study operations, and the Genospace personalized medicine platform that transforms patient data into actionable treatment insights.

Product overview

SCRI at Mary Crowley operates as a unified cancer research organization offering a portfolio of services including clinical trials across multiple cancer types, oncology-focused contract research organization (CRO) services, centralized site management organization (SMO) services, and personalized medicine capabilities through the Genospace platform. The organization provides these services through its partner offerings including Accelero™, Innovation Science & Technology, and the broader personalized medicine platform, enabling patients in North Texas access to cutting-edge therapies through an expanded clinical trial menu.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trials Clinical trial offerings across a broad list of cancer types, providing cancer patients in North Texas with access to cutting-edge therapies and research-based treatments through SCRI at Mary Crowley.
• Oncology-Focused CRO A contract research organization service focused on oncology research, offered as part of SCRI's partner solutions.
• Centralized SMO A site management organization service providing centralized clinical trial site operations, part of SCRI's partner offerings.
• Innovation, Science & Technology / Personalized Medicine Innovation, science and technology services focused on personalized medicine, enabling tailored treatment approaches for cancer patients through data-driven insights.
• Accelero™ A service offering within SCRI's partner solutions, providing partner-facing capabilities as referenced in the navigation menu.

Named customers2 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• Sarah Cannon Research Institute (SCRI)coreStrategic or Co-development Partner · 1 January 2025Mary Crowley Cancer Research joined Sarah Cannon Research Institute in January 2025 under the unified banner of SCRI at Mary Crowley. This merger provides patients with expanded clinical trial options, strengthened research capabilities, and access to Genospace personalized medicine platform.
• Texas OncologycoreStrategic or Co-development PartnerSCRI at Mary Crowley is supported by locally trusted and globally recognized Texas Oncology physicians. Texas Oncology provides the physician network that refers patients to clinical trials and provides ongoing cancer care support.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Market position

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/mccrchopelives
• YouTubeyoutube.com/@SarahCannonResearchInstitute
• Facebookfacebook.com/144078465644717
• LinkedInlinkedin.com/company/mary-crowley-cancer-research-centers

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mary Crowley Cancer Research Centers